1 Hasler G, Preisig M, Müller T, Holsboer-Trachsler E, Conus P, Aubry J, et al. Behandlungsempfehlungen für bipolare Störungen. Schweiz Med Forum. 2011;11(18):308–313.
2 Greil W, von Stralendorff I. Bipolare Störungen: Medikamentöse Therapie. In: Voderholzer U, Hohagen F, eds. Therapie psychischer Erkrankungen. State of the Art. 6. Auflage: Elsevier; 2011:180–191.
3 Hasler G, Preisig M, Müller T, Kawohl W, Seifritz E, Holsboer-Trachsler E, et al. Behandlungsempfehlungen für bipolare Störungen: Update 2015. Schweiz Med Forum.2015;15(20–21):486–494.
4 Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Bond DJ, Frey BN, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord.2018;20(2):97–170.
5 Malhi GS, Adams D, Lampe L, Paton M, O’Connor N, Newton LA, et al. Clinical practice recommendations for bipolar disorder. Acta Psychiatr Scand Suppl.2009(439):27–46.
6 Birmaher B, Axelson D, Goldstein B, Strober M, Gill MK, Hunt J, et al. Four-year longitudinal course of children and adolescents with bipolar spectrum disorders: the Course and Outcome of Bipolar Youth (COBY) study. Am J Psychiatry.2009;166(7):795–804.
7 Ludwig B, Dwivedi Y. Dissecting bipolar disorder complexity through epigenomic approach. Mol Psychiatry.2016;21(11):1490–1498.
8 Kleindienst N, Greil W. Are illness concepts a powerful predictor of adherence to prophylactic treatment in bipolar disorder? J Clin Psychiatry.2004;65(7):966–974.
9 Zaretsky A. Targeted psychosocial interventions for bipolar disorder. Bipolar Disord.2003;5 Suppl 2:80–87.
10 Colom F, Vieta E. A perspective on the use of psychoeducation, cognitive-behavioral therapy and interpersonal therapy for bipolar patients. Bipolar Disord.2004;6(6):480–486.
11 Reinares M, Sanchez-Moreno J, Fountoulakis KN. Psychosocial interventions in bipolar disorder: what, for whom, and when. J Affect Disord.2014;156:46–55.
12 Murray G, Leitan ND, Thomas N, Michalak EE, Johnson SL, Jones S, et al. Towards recovery-oriented psychosocial interventions for bipolar disorder: Quality of life outcomes, stage-sensitive treatments, and mindfulness mechanisms. Clinical Psychology Review.2017;52:148–163.
13 Reinares M, Colom F, Sanchez-Moreno J, Torrent C, Martinez-Aran A, Comes M, et al. Impact of caregiver group psychoeducation on the course and outcome of bipolar patients in remission: a randomized controlled trial. Bipolar Disord.2008;10(4):511–519.
14 Smith DJ, Griffiths E, Poole R, di Florio A, Barnes E, Kelly MJ, et al. Beating Bipolar: exploratory trial of a novel Internet-based psychoeducational treatment for bipolar disorder. Bipolar Disord.2011;13(5–6):571–577.
15 Salcedo S, Gold AK, Sheikh S, Marcus PH, Nierenberg AA, Deckersbach T, et al. Empirically supported psychosocial interventions for bipolar disorder: Current state of the research. J Affect Disord.2016;201:203–214.
16 Dean OM, Gliddon E, Van Rheenen TE, Giorlando F, Davidson SK, Kaur M, et al. An update on adjunctive treatment options for bipolar disorder. Bipolar Disord.2018;20(2):87–96.
17 Miklowitz DJ. A review of evidence-based psychosocial interventions for bipolar disorder. J Clin Psychiatry.2006;67 Suppl 11:28–33.
18 Torrent C, Bonnin Cdel M, Martinez-Aran A, Valle J, Amann BL, Gonzalez-Pinto A, et al. Efficacy of functional remediation in bipolar disorder: a multicenter randomized controlled study. Am J Psychiatry.2013;170(8):852–859.
19 Miklowitz DJ, Cipriani A, Goodwin GM. Network meta-analysis: drawing conclusions regarding trials of psychosocial interventions for bipolar disorder. Br J Psychiatry.2017;211(6):334–336.
20 Modini M, Tan L, Brinchmann B, Wang MJ, Killackey E, Glozier N, et al. Supported employment for people with severe mental illness: systematic review and meta-analysis of the international evidence. Br J Psychiatry.2016;209(1):14–22.
21 Metcalfe JD, Drake RE, Bond GR. Economic, Labor, and Regulatory Moderators of the Effect of Individual Placement and Support Among People With Severe Mental Illness: A Systematic Review and Meta-analysis. Schizophr Bull.2018;44(1):22–31.
22 Burns T, Catty J, Becker T, Drake RE, Fioritti A, Knapp M, et al. The effectiveness of supported employment for people with severe mental illness: a randomised controlled trial. Lancet.2007;370(9593):1146–1152.
23 Lauber C, Kawohl W. Supported Employment. In: Rössler W, Kawohl W, eds. Soziale Psychiatrie. Das Handbuch für die psychosoziale Praxis. Band 2. Stuttgart: Kohlhammer; 2013.
24 Rössler W, Kawohl W, Nordt C, Haker H, Rüsch N, Hengartner MP. «Placement Budgets» for Supported Employment—Impact on Quality of Life in a Multicenter Randomized Controlled Trial. Frontiers in Psychiatry.2018;9.
25 Calabrese JR, Keck PE, Jr., Starace A, Lu K, Ruth A, Laszlovszky I, et al. Efficacy and safety of low- and high-dose cariprazine in acute and mixed mania associated with bipolar I disorder: a double-blind, placebo-controlled study. J Clin Psychiatry.2015;76(3):284–292.
26 Ogawa Y, Tajika A, Takeshima N, Hayasaka Y, Furukawa TA. Mood stabilizers and antipsychotics for acute mania: a systematic review and meta-analysis of combination/augmentation therapy versus monotherapy. CNS Drugs.2014;28(11):989–1003.
27 Cipriani A, Barbui C, Salanti G, Rendell J, Brown R, Stockton S, et al. Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. Lancet.2011;378(9799):1306–1315.
28 Yildiz A, Nikodem M, Vieta E, Correll CU, Baldessarini RJ. A network meta-analysis on comparative efficacy and all-cause discontinuation of antimanic treatments in acute bipolar mania. Psychol Med.2015;45(2):299–317.
29 DGBS/DGPPN. S3-Leitlinie Diagnostik und Therapie bipolarer Störungen. Berlin: Springer; 2013.
30 Grunze H, Vieta E, Goodwin GM, Bowden C, Licht RW, Moller HJ, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2010 on the treatment of acute bipolar depression. World J Biol Psychiatry.2010;11(2):81–109.
31 Calabrese JR, Keck PE, Jr., Macfadden W, Minkwitz M, Ketter TA, Weisler RH, et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry.2005;162(7):1351–1360.
32 Thase ME, Macfadden W, Weisler RH, Chang W, Paulsson B, Khan A, et al. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol.2006;26(6):600–609.
33 Young AH, McElroy SL, Bauer M, Philips N, Chang W, Olausson B, et al. A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I). J Clin Psychiatry.2010;71(2):150–162.
34 McElroy SL, Weisler RH, Chang W, Olausson B, Paulsson B, Brecher M, et al. A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). J Clin Psychiatry.2010;71(2):163–174.
35 Gershon S, Chengappa KN, Malhi GS. Lithium specificity in bipolar illness: a classic agent for the classic disorder. Bipolar Disord.2009;11 Suppl 2:34–44.
36 Selle V, Schalkwijk S, Vázquez G, Baldessarini R. Treatments for Acute Bipolar Depression: Meta-analyses of Placebo-controlled, Monotherapy Trials of Anticonvulsants, Lithium and Antipsychotics. Pharmacopsychiatry.2014;47(02):43–52.
37 Geddes JR, Calabrese JR, Goodwin GM. Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials. Br J Psychiatry.2009;194(1):4–9.
38 Calabrese JR, Huffman RF, White RL, Edwards S, Thompson TR, Ascher JA, et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disord.2008;10(2):323–333.
39 Loebel A, Cucchiaro J, Silva R, Kroger H, Sarma K, Xu J, et al. Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry.2014;171(2):169–177.
40 Loebel A, Cucchiaro J, Silva R, Kroger H, Hsu J, Sarma K, et al. Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry.2014;171(2):160–168.
41 Ragguett RM, McIntyre RS. Cariprazine for the treatment of bipolar depression: a review. Expert Rev Neurother.2019:1–7.
42 Durgam S, Earley W, Lipschitz A, Guo H, Laszlovszky I, Nemeth G, et al. An 8-Week Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Cariprazine in Patients With Bipolar I Depression. Am J Psychiatry.2016;173(3):271–281.
43 Sachs GS, Nierenberg AA, Calabrese JR, Marangell LB, Wisniewski SR, Gyulai L, et al. Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med.2007;356(17):1711–1722.
44 Gijsman HJ, Geddes JR, Rendell JM, Nolen WA, Goodwin GM. Antidepressants for bipolar depression: a systematic review of randomized, controlled trials. Am J Psychiatry.2004;161(9):1537–1547.
45 Amsterdam JD, Shults J. Efficacy and safety of long-term fluoxetine versus lithium monotherapy of bipolar II disorder: a randomized, double-blind, placebo-substitution study. Am J Psychiatry.2010;167(7):792–800.
46 McGirr A, Vöhringer PA, Ghaemi SN, Lam RW, Yatham LN. Safety and efficacy of adjunctive second-generation antidepressant therapy with a mood stabiliser or an atypical antipsychotic in acute bipolar depression: a systematic review and meta-analysis of randomised placebo-controlled trials. The Lancet Psychiatry.2016;3(12):1138–1146.
47 Haeberle A, Greil W, Russmann S, Grohmann R. Mono- and combination drug therapies in hospitalized patients with bipolar depression. Data from the European drug surveillance program AMSP. BMC Psychiatry.2012;12:153.
48 Greil W, Haberle A, Haueis P, Grohmann R, Russmann S. Pharmacotherapeutic trends in 2231 psychiatric inpatients with bipolar depression from the International AMSP Project between 1994 and 2009. J Affect Disord.2012;136(3):534–542.
49 Reinares M, Bonnin Cdel M, Hidalgo-Mazzei D, Undurraga J, Mur M, Nieto E, et al. Making sense of DSM-5 mania with depressive features. Aust N Z J Psychiatry.2015;49(6):540–549.
50 Persons JE, Coryell WH, Solomon DA, Keller MB, Endicott J, Fiedorowicz JG. Mixed state and suicide: Is the effect of mixed state on suicidal behavior more than the sum of its parts? Bipolar Disord.2018;20(1):35–41.
51 Cuomo A, Nikolova VL, Yalin N, Arnone D, Fagiolini A, Young AH. Pharmacological treatment of mixed states. CNS Spectr.2017;22(2):186–195.
52 Suppes T, Silva R, Cucchiaro J, Mao Y, Targum S, Streicher C, et al. Lurasidone for the Treatment of Major Depressive Disorder With Mixed Features: A Randomized, Double-Blind, Placebo-Controlled Study. Am J Psychiatry.2016;173(4):400–407.
53 Grunze H, Vieta E, Goodwin GM, Bowden C, Licht RW, Azorin JM, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Acute and long-term treatment of mixed states in bipolar disorder. World J Biol Psychiatry.2018;19(1):2–58.
54 Szegedi A, Durgam S, Mackle M, Yu SY, Wu X, Mathews M, et al. Randomized, Double-Blind, Placebo-Controlled Trial of Asenapine Maintenance Therapy in Adults With an Acute Manic or Mixed Episode Associated With Bipolar I Disorder. Am J Psychiatry.2018;175(1):71–79.
55 Fountoulakis KN, Kontis D, Gonda X, Yatham LN. A systematic review of the evidence on the treatment of rapid cycling bipolar disorder. Bipolar Disord.2013;15(2):115–137.
56 Ghaemi SN, Ostacher MM, El-Mallakh RS, Borrelli D, Baldassano CF, Kelley ME, et al. Antidepressant discontinuation in bipolar depression: a Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) randomized clinical trial of long-term effectiveness and safety. J Clin Psychiatry.2010;71(4):372–380.
57 Bauer M, Glenn T, Grof P, Schmid R, Pfennig A, Whybrow PC. Subsyndromal mood symptoms: a useful concept for maintenance studies of bipolar disorder? Psychopathology.2010;43(1):1–7.
58 Brieger P. [Subaffective disorders: dysthymia and cyclothymia]. MMW Fortschr Med.2010;152(3):31–33.
59 Brieger P, Marneros A. Dysthymia and cyclothymia: historical origins and contemporary development. J Affect Disord.1997;45(3):117–126.
60 Pfennig A, Bschor T, Baghai T, Braunig P, Brieger P, Falkai P, et al. S3-Leitlinie zur Diagnostik und Therapie bipolarer Störungen Entwicklungsprozess und wesentliche Empfehlungen Nervenarzt.2012;83(5):568–586.
61 Berk M, Post R, Ratheesh A, Gliddon E, Singh A, Vieta E, et al. Staging in bipolar disorder: from theoretical framework to clinical utility. World Psychiatry.2017;16(3):236–244.
62 Altshuler L, Suppes T, Black D, Nolen WA, Keck PE, Jr., Frye MA, et al. Impact of antidepressant discontinuation after acute bipolar depression remission on rates of depressive relapse at 1-year follow-up. Am J Psychiatry.2003;160(7):1252–1262.
63 Miura T, Noma H, Furukawa TA, Mitsuyasu H, Tanaka S, Stockton S, et al. Comparative efficacy and tolerability of pharmacological treatments in the maintenance treatment of bipolar disorder: a systematic review and network meta-analysis. Lancet Psychiatry.2014;1(5):351–359.
64 BALANCE investigators and collaborators, Geddes JR, Goodwin GM, Rendell J, Azorin JM, et al. Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial. Lancet.2010;375(9712):385–395.
65 Greil W, Kleindienst N, Erazo N, Muller-Oerlinghausen B. Differential response to lithium and carbamazepine in the prophylaxis of bipolar disorder. J Clin Psychopharmacol.1998;18(6):455–460.
66 Severus WE, Kleindienst N, Evoniuk G, Bowden C, Moller HJ, Bohus M, et al. Is the polarity of relapse/recurrence in bipolar-I disorder patients related to serum lithium levels? Results from an empirical study. J Affect Disord.2009;115(3):466–470.
67 Cipriani A, Smith K, Burgess S, Carney S, Goodwin G, Geddes J. Lithium versus antidepressants in the long-term treatment of unipolar affective disorder. Cochrane Database Syst Rev.2006(4):CD003492.
68 Weisler RH, Nolen WA, Neijber A, Hellqvist A, Paulsson B, Trial 144 Study I. Continuation of quetiapine versus switching to placebo or lithium for maintenance treatment of bipolar I disorder (Trial 144: a randomized controlled study). J Clin Psychiatry.2011;72(11):1452–1464.
69 Keck PE, Jr., Calabrese JR, McQuade RD, Carson WH, Carlson BX, Rollin LM, et al. A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. J Clin Psychiatry.2006;67(4):626–637.
70 Keck PE, Jr., Calabrese JR, McIntyre RS, McQuade RD, Carson WH, Eudicone JM, et al. Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo. J Clin Psychiatry.2007;68(10):1480–1491.
71 Tohen M, Greil W, Calabrese JR, Sachs GS, Yatham LN, Oerlinghausen BM, et al. Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial. Am J Psychiatry.2005;162(7):1281–1290.
72 Tohen M, Sutton VK, Calabrese JR, Sachs GS, Bowden CL. Maintenance of response following stabilization of mixed index episodes with olanzapine monotherapy in a randomized, double-blind, placebo-controlled study of bipolar 1 disorder. J Affect Disord.2009;116(1–2):43–50.
73 Tohen M, Ketter TA, Zarate CA, Suppes T, Frye M, Altshuler L, et al. Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. Am J Psychiatry.2003;160(7):1263–1271.
74 Cipriani A, Reid K, Young AH, Macritchie K, Geddes J. Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder. Cochrane Database Syst Rev.2013(10):CD003196.
75 van der Loos ML, Mulder P, Hartong EG, Blom MB, Vergouwen AC, van Noorden MS, et al. Long-term outcome of bipolar depressed patients receiving lamotrigine as add-on to lithium with the possibility of the addition of paroxetine in nonresponders: a randomized, placebo-controlled trial with a novel design. Bipolar Disord.2011;13(1):111–117.
76 Vieta E, Nieto E, Autet A, Rosa AR, Goikolea JM, Cruz N, et al. A long-term prospective study on the outcome of bipolar patients treated with long-acting injectable risperidone. World J Biol Psychiatry.2008;9(3):219–224.
77 Altamura AC, Mundo E, Dell’Osso B, Tacchini G, Buoli M, Calabrese JR. Quetiapine and classical mood stabilizers in the long-term treatment of Bipolar Disorder: a 4-year follow-up naturalistic study. J Affect Disord.2008;110(1–2):135–141.
78 Calabrese JR, Pikalov A, Streicher C, Cucchiaro J, Mao Y, Loebel A. Lurasidone in combination with lithium or valproate for the maintenance treatment of bipolar I disorder. Eur Neuropsychopharmacol.2017;27(9):865–876.
79 Kessing LV, Hansen MG, Andersen PK, Angst J. The predictive effect of episodes on the risk of recurrence in depressive and bipolar disorders - a life-long perspective. Acta Psychiatr Scand.2004;109(5):339–344.
80 Merikangas KR, Jin R, He JP, Kessler RC, Lee S, Sampson NA, et al. Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Arch Gen Psychiatry.2011;68(3):241–251.
81 Young AH, Calabrese JR, Gustafsson U, Berk M, McElroy SL, Thase ME, et al. Quetiapine monotherapy in bipolar II depression: combined data from four large, randomized studies. Int J Bipolar Disord.2013;1:10.
82 Datto C, Pottorf WJ, Feeley L, LaPorte S, Liss C. Bipolar II compared with bipolar I disorder: baseline characteristics and treatment response to quetiapine in a pooled analysis of five placebo-controlled clinical trials of acute bipolar depression. Ann Gen Psychiatry.2016;15:9.
83 Pacchiarotti I, Bond DJ, Baldessarini RJ, Nolen WA, Grunze H, Licht RW, et al. The International Society for Bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders. Am J Psychiatry.2013;170(11):1249–1262.
84 Tondo L, Baldessarini RJ, Floris G. Long-term clinical effectiveness of lithium maintenance treatment in types I and II bipolar disorders. Br J Psychiatry Suppl.2001;41:s184–190.
85 Amsterdam JD, Shults J. Efficacy and mood conversion rate of short-term fluoxetine monotherapy of bipolar II major depressive episode. J Clin Psychopharmacol.2010;30(3):306–311.
86 Amsterdam JD, Lorenzo-Luaces L, Soeller I, Li SQ, Mao JJ, DeRubeis RJ. Safety and effectiveness of continuation antidepressant versus mood stabilizer monotherapy for relapse-prevention of bipolar II depression: A randomized, double-blind, parallel-group, prospective study. J Affect Disord.2015;185:31–37.
87 Ng F, Mammen OK, Wilting I, Sachs GS, Ferrier IN, Cassidy F, et al. The International Society for Bipolar Disorders (ISBD) consensus guidelines for the safety monitoring of bipolar disorder treatments. Bipolar Disord.2009;11(6):559–595.
88 Hasler G, Wolf A. Toward stratified treatments for bipolar disorders. Eur Neuropsychopharmacol.2015;25(3):283–294.
89 Hasler G, Drevets WC, Gould TD, Gottesman, II, Manji HK. Toward constructing an endophenotype strategy for bipolar disorders. Biol Psychiatry.2006;60(2):93–105.